Epstein-Barr Virus LMP1-Mediated Oncogenecity View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2000-2016

FUNDING AMOUNT

10577482 USD

ABSTRACT

DESCRIPTION (provided by applicant): Epstein - Barr virus is an important cause Hodgkin's Disease, Lymphomas, and Lymphoproliferative Diseases, particularly in people with HIV infection and other immune- compromised states. The EBV oncoprotein Latent Membrane Protein 1 transforms B-cells through 2 essential signaling domains for B cell growth: Transformation effect site 1, which activates non- canonical NFkB and site 2, which activates canonical NFkB. Both NFkB pathways are necessary for infected cell growth and survival. To discover key components of LMP1 affected NFkB pathways, our AIMS are to: (1) Characterize key B-cell proteins required for LMP1 TES2 canonical NFkB activation for their role in TRAF6 and IKK activation, NEMO ubiquitination, and nuclear RelA phosphorylation. Candidates for missing kinases, phosphatases, E3 ligases, and scaffolds have been identified through a genome wide siRNA screen in 293 cells and will be evaluated in B cells. (2) Key B-cell proteins required for LMP1 TES1 non-canonical NFkB activation will be identified. This aim will focus on unique LMP1 effects through TRAFs, will employ LMP1 and TRAF genetic analyses and will identify novel cell proteins critical for LMP1-mediated non-canonical NFkB activation. (3) Identify combinations of AIM 1 and 2 target proteins knockdowns that create synthetic lethal effects, when both are depleted from EBV-transformed B cells. AIM3 experiments exploit what we learn in AIMS 1 and 2 to identify the Achilles' Heel of EBV-associated lymphomas. NFkB small molecule inhibitors that are not specific for LMP1-mediated NFkB activation will likely be limited by side-effects, including inhibition of critical immune responses. These studies specifically address NCI goals outlined in PA10-290 by determining the mechanism by which EBV affects tumor promotion and progression, by discovering novel targets for rational drug discovery for the treatment of persons afflicted with AIDS-defining malignancies, and by using combinatorial genomic methodologies to further development of therapeutic agents. Our discoveries will elucidate new key targets in NFkB activation and more broadly advance priority target-based tool compound discovery. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=8971998

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2206", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "amount": {
      "currency": "USD", 
      "type": "MonetaryAmount", 
      "value": "10577482"
    }, 
    "description": "DESCRIPTION (provided by applicant): Epstein - Barr virus is an important cause Hodgkin's Disease, Lymphomas, and Lymphoproliferative Diseases, particularly in people with HIV infection and other immune- compromised states. The EBV oncoprotein Latent Membrane Protein 1 transforms B-cells through 2 essential signaling domains for B cell growth: Transformation effect site 1, which activates non- canonical NFkB and site 2, which activates canonical NFkB. Both NFkB pathways are necessary for infected cell growth and survival. To discover key components of LMP1 affected NFkB pathways, our AIMS are to: (1) Characterize key B-cell proteins required for LMP1 TES2 canonical NFkB activation for their role in TRAF6 and IKK activation, NEMO ubiquitination, and nuclear RelA phosphorylation. Candidates for missing kinases, phosphatases, E3 ligases, and scaffolds have been identified through a genome wide siRNA screen in 293 cells and will be evaluated in B cells. (2) Key B-cell proteins required for LMP1 TES1 non-canonical NFkB activation will be identified. This aim will focus on unique LMP1 effects through TRAFs, will employ LMP1 and TRAF genetic analyses and will identify novel cell proteins critical for LMP1-mediated non-canonical NFkB activation. (3) Identify combinations of AIM 1 and 2 target proteins knockdowns that create synthetic lethal effects, when both are depleted from EBV-transformed B cells. AIM3 experiments exploit what we learn in AIMS 1 and 2 to identify the Achilles' Heel of EBV-associated lymphomas. NFkB small molecule inhibitors that are not specific for LMP1-mediated NFkB activation will likely be limited by side-effects, including inhibition of critical immune responses. These studies specifically address NCI goals outlined in PA10-290 by determining the mechanism by which EBV affects tumor promotion and progression, by discovering novel targets for rational drug discovery for the treatment of persons afflicted with AIDS-defining malignancies, and by using combinatorial genomic methodologies to further development of therapeutic agents. Our discoveries will elucidate new key targets in NFkB activation and more broadly advance priority target-based tool compound discovery.", 
    "endDate": "2016-11-30T00:00:00Z", 
    "funder": {
      "id": "https://www.grid.ac/institutes/grid.48336.3a", 
      "type": "Organization"
    }, 
    "id": "sg:grant.2474730", 
    "identifier": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "2474730"
        ]
      }, 
      {
        "name": "nih_id", 
        "type": "PropertyValue", 
        "value": [
          "R01CA085180"
        ]
      }
    ], 
    "inLanguage": [
      "en"
    ], 
    "keywords": [
      "oncogenecity", 
      "NFkB pathway", 
      "site 2", 
      "treatment", 
      "synthetic lethal effect", 
      "survival", 
      "malignancy", 
      "novel target", 
      "Aim 1", 
      "PA10", 
      "other immune-", 
      "NFkB activation", 
      "Achilles' heel", 
      "inhibition", 
      "description", 
      "key B", 
      "applicants", 
      "canonical NFkB.", 
      "cell protein", 
      "novel cell protein", 
      "aim", 
      "infected cell growth", 
      "state", 
      "tumor promotion", 
      "persons", 
      "lymphoma", 
      "key component", 
      "AIDS", 
      "progression", 
      "target proteins", 
      "advance priority target", 
      "TRAF", 
      "cells", 
      "LMP1-mediated NFkB activation", 
      "scaffolds", 
      "candidates", 
      "canonical NFkB", 
      "critical immune responses", 
      "nuclear RelA phosphorylation", 
      "side-effects", 
      "HIV infection", 
      "unique LMP1 effects", 
      "tool compound discovery", 
      "non-canonical NFkB activation", 
      "kinase", 
      "domain", 
      "genome", 
      "Lymphoproliferative Diseases", 
      "TRAF6", 
      "development", 
      "combination", 
      "NCI goal", 
      "NFkB small molecule inhibitors", 
      "mechanism", 
      "EBV", 
      "Transformation effect site 1", 
      "discovery", 
      "IKK activation", 
      "E3 ligases", 
      "latent membrane protein 1", 
      "cell growth", 
      "TRAF genetic analyses", 
      "combinatorial genomic methodologies", 
      "Lymphomas", 
      "wide siRNA screen", 
      "AIM3 experiments", 
      "therapeutic agents", 
      "AIMS", 
      "NEMO ubiquitination", 
      "Epstein-Barr virus", 
      "important cause Hodgkin's Disease", 
      "new key target", 
      "study", 
      "rational drug discovery", 
      "phosphatase", 
      "people", 
      "LMP1", 
      "Aims 1", 
      "LMP1 TES2 canonical NFkB activation", 
      "role", 
      "LMP1 TES1 non-canonical NFkB activation"
    ], 
    "name": "Epstein-Barr Virus LMP1-Mediated Oncogenecity", 
    "recipient": [
      {
        "id": "https://www.grid.ac/institutes/grid.62560.37", 
        "type": "Organization"
      }, 
      {
        "affiliation": {
          "id": "https://www.grid.ac/institutes/grid.62560.37", 
          "name": "BRIGHAM AND WOMEN'S HOSPITAL", 
          "type": "Organization"
        }, 
        "familyName": "KIEFF", 
        "givenName": "ELLIOTT D", 
        "id": "sg:person.010135371414.57", 
        "type": "Person"
      }, 
      {
        "member": "sg:person.010135371414.57", 
        "roleName": "PI", 
        "type": "Role"
      }
    ], 
    "sameAs": [
      "https://app.dimensions.ai/details/grant/grant.2474730"
    ], 
    "sdDataset": "grants", 
    "sdDatePublished": "2019-03-07T12:14", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_6.xml.gz", 
    "startDate": "2000-09-20T00:00:00Z", 
    "type": "MonetaryGrant", 
    "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=8971998"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2474730'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2474730'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2474730'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2474730'


 

This table displays all metadata directly associated to this object as RDF triples.

128 TRIPLES      19 PREDICATES      104 URIs      95 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:grant.2474730 schema:about anzsrc-for:2206
2 anzsrc-for:2211
3 schema:amount N25e33c9648a64c02b2506c97d3f29072
4 schema:description DESCRIPTION (provided by applicant): Epstein - Barr virus is an important cause Hodgkin's Disease, Lymphomas, and Lymphoproliferative Diseases, particularly in people with HIV infection and other immune- compromised states. The EBV oncoprotein Latent Membrane Protein 1 transforms B-cells through 2 essential signaling domains for B cell growth: Transformation effect site 1, which activates non- canonical NFkB and site 2, which activates canonical NFkB. Both NFkB pathways are necessary for infected cell growth and survival. To discover key components of LMP1 affected NFkB pathways, our AIMS are to: (1) Characterize key B-cell proteins required for LMP1 TES2 canonical NFkB activation for their role in TRAF6 and IKK activation, NEMO ubiquitination, and nuclear RelA phosphorylation. Candidates for missing kinases, phosphatases, E3 ligases, and scaffolds have been identified through a genome wide siRNA screen in 293 cells and will be evaluated in B cells. (2) Key B-cell proteins required for LMP1 TES1 non-canonical NFkB activation will be identified. This aim will focus on unique LMP1 effects through TRAFs, will employ LMP1 and TRAF genetic analyses and will identify novel cell proteins critical for LMP1-mediated non-canonical NFkB activation. (3) Identify combinations of AIM 1 and 2 target proteins knockdowns that create synthetic lethal effects, when both are depleted from EBV-transformed B cells. AIM3 experiments exploit what we learn in AIMS 1 and 2 to identify the Achilles' Heel of EBV-associated lymphomas. NFkB small molecule inhibitors that are not specific for LMP1-mediated NFkB activation will likely be limited by side-effects, including inhibition of critical immune responses. These studies specifically address NCI goals outlined in PA10-290 by determining the mechanism by which EBV affects tumor promotion and progression, by discovering novel targets for rational drug discovery for the treatment of persons afflicted with AIDS-defining malignancies, and by using combinatorial genomic methodologies to further development of therapeutic agents. Our discoveries will elucidate new key targets in NFkB activation and more broadly advance priority target-based tool compound discovery.
5 schema:endDate 2016-11-30T00:00:00Z
6 schema:funder https://www.grid.ac/institutes/grid.48336.3a
7 schema:identifier Ncfa669cae99d4dd99d79e4950195b27b
8 Ne22f61a407934b74b80de2f3b8523c84
9 schema:inLanguage en
10 schema:keywords AIDS
11 AIM3 experiments
12 AIMS
13 Achilles' heel
14 Aim 1
15 Aims 1
16 E3 ligases
17 EBV
18 Epstein-Barr virus
19 HIV infection
20 IKK activation
21 LMP1
22 LMP1 TES1 non-canonical NFkB activation
23 LMP1 TES2 canonical NFkB activation
24 LMP1-mediated NFkB activation
25 Lymphomas
26 Lymphoproliferative Diseases
27 NCI goal
28 NEMO ubiquitination
29 NFkB activation
30 NFkB pathway
31 NFkB small molecule inhibitors
32 PA10
33 TRAF
34 TRAF genetic analyses
35 TRAF6
36 Transformation effect site 1
37 advance priority target
38 aim
39 applicants
40 candidates
41 canonical NFkB
42 canonical NFkB.
43 cell growth
44 cell protein
45 cells
46 combination
47 combinatorial genomic methodologies
48 critical immune responses
49 description
50 development
51 discovery
52 domain
53 genome
54 important cause Hodgkin's Disease
55 infected cell growth
56 inhibition
57 key B
58 key component
59 kinase
60 latent membrane protein 1
61 lymphoma
62 malignancy
63 mechanism
64 new key target
65 non-canonical NFkB activation
66 novel cell protein
67 novel target
68 nuclear RelA phosphorylation
69 oncogenecity
70 other immune-
71 people
72 persons
73 phosphatase
74 progression
75 rational drug discovery
76 role
77 scaffolds
78 side-effects
79 site 2
80 state
81 study
82 survival
83 synthetic lethal effect
84 target proteins
85 therapeutic agents
86 tool compound discovery
87 treatment
88 tumor promotion
89 unique LMP1 effects
90 wide siRNA screen
91 schema:name Epstein-Barr Virus LMP1-Mediated Oncogenecity
92 schema:recipient Nee75b947126a4412af942ba9cca32dbc
93 sg:person.010135371414.57
94 https://www.grid.ac/institutes/grid.62560.37
95 schema:sameAs https://app.dimensions.ai/details/grant/grant.2474730
96 schema:sdDatePublished 2019-03-07T12:14
97 schema:sdLicense https://scigraph.springernature.com/explorer/license/
98 schema:sdPublisher N891cb231f23b4feaa6dfd063069a3d1a
99 schema:startDate 2000-09-20T00:00:00Z
100 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=8971998
101 sgo:license sg:explorer/license/
102 sgo:sdDataset grants
103 rdf:type schema:MonetaryGrant
104 N25e33c9648a64c02b2506c97d3f29072 schema:currency USD
105 schema:value 10577482
106 rdf:type schema:MonetaryAmount
107 N891cb231f23b4feaa6dfd063069a3d1a schema:name Springer Nature - SN SciGraph project
108 rdf:type schema:Organization
109 Ncfa669cae99d4dd99d79e4950195b27b schema:name nih_id
110 schema:value R01CA085180
111 rdf:type schema:PropertyValue
112 Ne22f61a407934b74b80de2f3b8523c84 schema:name dimensions_id
113 schema:value 2474730
114 rdf:type schema:PropertyValue
115 Nee75b947126a4412af942ba9cca32dbc schema:member sg:person.010135371414.57
116 schema:roleName PI
117 rdf:type schema:Role
118 anzsrc-for:2206 schema:inDefinedTermSet anzsrc-for:
119 rdf:type schema:DefinedTerm
120 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
121 rdf:type schema:DefinedTerm
122 sg:person.010135371414.57 schema:affiliation https://www.grid.ac/institutes/grid.62560.37
123 schema:familyName KIEFF
124 schema:givenName ELLIOTT D
125 rdf:type schema:Person
126 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
127 https://www.grid.ac/institutes/grid.62560.37 schema:name BRIGHAM AND WOMEN'S HOSPITAL
128 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...